These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
526 related articles for article (PubMed ID: 34358067)
1. Hypomethylating Chemotherapeutic Agents as Therapy for Myelodysplastic Syndromes and Prevention of Acute Myeloid Leukemia. Sorrentino VG; Thota S; Gonzalez EA; Rameshwar P; Chang VT; Etchegaray JP Pharmaceuticals (Basel); 2021 Jul; 14(7):. PubMed ID: 34358067 [TBL] [Abstract][Full Text] [Related]
2. Results of phase 2 randomized study of low-dose decitabine with or without valproic acid in patients with myelodysplastic syndrome and acute myelogenous leukemia. Issa JP; Garcia-Manero G; Huang X; Cortes J; Ravandi F; Jabbour E; Borthakur G; Brandt M; Pierce S; Kantarjian HM Cancer; 2015 Feb; 121(4):556-61. PubMed ID: 25336333 [TBL] [Abstract][Full Text] [Related]
3. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials. Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795 [TBL] [Abstract][Full Text] [Related]
4. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine. Feld J; Tremblay D; Navada SC; Silverman LR Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098 [TBL] [Abstract][Full Text] [Related]
5. Lack of objective response of myelodysplastic syndromes and acute myeloid leukemia to decitabine after failure of azacitidine. Duong VH; Bhatnagar B; Zandberg DP; Vannorsdall EJ; Tidwell ML; Chen Q; Baer MR Leuk Lymphoma; 2015 Jun; 56(6):1718-22. PubMed ID: 25263320 [TBL] [Abstract][Full Text] [Related]
6. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis. Liu W; Zhou Z; Chen L; Wang X Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056 [TBL] [Abstract][Full Text] [Related]
7. The euphoria of hypomethylating agents in MDS and AML: is it justified? Sekeres MA Best Pract Res Clin Haematol; 2013 Sep; 26(3):275-8. PubMed ID: 24309530 [TBL] [Abstract][Full Text] [Related]
8. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions. Short NJ; Kantarjian H Am J Hematol; 2022 Dec; 97(12):1616-1626. PubMed ID: 35871436 [TBL] [Abstract][Full Text] [Related]
9. Different mechanisms of drug resistance to hypomethylating agents in the treatment of myelodysplastic syndromes and acute myeloid leukemia. Šimoničová K; Janotka Ľ; Kavcová H; Sulová Z; Breier A; Messingerova L Drug Resist Updat; 2022 Mar; 61():100805. PubMed ID: 35227933 [TBL] [Abstract][Full Text] [Related]
10. Digging deep into "dirty" drugs - modulation of the methylation machinery. Pleyer L; Greil R Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693 [TBL] [Abstract][Full Text] [Related]
11. Clinical results with the DNA hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in patients with myelodysplastic syndromes: an update. Joeckel TE; Lübbert M Semin Hematol; 2012 Oct; 49(4):330-41. PubMed ID: 23079063 [TBL] [Abstract][Full Text] [Related]
12. Optimizing DNA hypomethylating therapy in acute myeloid leukemia and myelodysplastic syndromes. Straube J; Lane SW; Vu T Bioessays; 2021 Oct; 43(10):e2100125. PubMed ID: 34463368 [TBL] [Abstract][Full Text] [Related]
13. Efficacy of epigenetic agents for older patients with acute myeloid leukemia and myelodysplastic syndrome in randomized controlled trials: a systematic review and network meta-analysis. Oh S; Kim E Clin Exp Med; 2023 Oct; 23(6):2705-2714. PubMed ID: 36964818 [TBL] [Abstract][Full Text] [Related]
14. Decitabine in the treatment of myelodysplastic syndromes. Saba HI Ther Clin Risk Manag; 2007 Oct; 3(5):807-17. PubMed ID: 18473005 [TBL] [Abstract][Full Text] [Related]
15. The emerging role of immune checkpoint based approaches in AML and MDS. Boddu P; Kantarjian H; Garcia-Manero G; Allison J; Sharma P; Daver N Leuk Lymphoma; 2018 Apr; 59(4):790-802. PubMed ID: 28679300 [TBL] [Abstract][Full Text] [Related]
17. A phase 1 clinical trial of vorinostat in combination with decitabine in patients with acute myeloid leukaemia or myelodysplastic syndrome. Kirschbaum M; Gojo I; Goldberg SL; Bredeson C; Kujawski LA; Yang A; Marks P; Frankel P; Sun X; Tosolini A; Eid JE; Lubiniecki GM; Issa JP Br J Haematol; 2014 Oct; 167(2):185-93. PubMed ID: 25040094 [TBL] [Abstract][Full Text] [Related]
18. Hypomethylating Agents and Immunotherapy: Therapeutic Synergism in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Wong KK; Hassan R; Yaacob NS Front Oncol; 2021; 11():624742. PubMed ID: 33718188 [TBL] [Abstract][Full Text] [Related]
19. BRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic Syndromes. Pericole FV; Lazarini M; de Paiva LB; Duarte ADSS; Vieira Ferro KP; Niemann FS; Roversi FM; Olalla Saad ST Front Oncol; 2019; 9():16. PubMed ID: 30761268 [TBL] [Abstract][Full Text] [Related]
20. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Yang H; Bueso-Ramos C; DiNardo C; Estecio MR; Davanlou M; Geng QR; Fang Z; Nguyen M; Pierce S; Wei Y; Parmar S; Cortes J; Kantarjian H; Garcia-Manero G Leukemia; 2014 Jun; 28(6):1280-8. PubMed ID: 24270737 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]